PDF(Pubmed)
Abstract：
This note aims to inspire through providing a personal view of the development and potential Drug Delivery Nanocarriers functionalized with polythyleneglycol (PEG). This polymer has been used extensively in Pharmaceutical Technology in a variety of compositions, including polyethylene oxide (PEO)-based surfactants. However, the concept of PEGylation, which started in the 70\'s, differs from the functionality of a surfactant, already discloses in the 50\'s. Here, we strictly adhere to the biological functionality of PEGylated nanocarriers intended to have a reduced interaction with proteins and, therefore, modify their biodistribution as well as facilitate their diffusion across mucus and other biological barriers. We analyze how this concept has evolved over the years and the benefit obtained so far in terms of marketed nanomedicines and provide the readers with a prospect view of the topic.
摘要：
本说明旨在通过提供个人观点的发展和潜在的药物递送纳米载体与聚乙二醇（PEG）功能化。这种聚合物已广泛用于制药技术中的各种组合物，包括聚环氧乙烷(PEO)基表面活性剂。然而,聚乙二醇化的概念，它始于70年代，不同于表面活性剂的功能，已经在50年代披露了。这里,我们严格遵守聚乙二醇化纳米载体的生物功能，旨在减少与蛋白质的相互作用，因此,改变它们的生物分布，并促进它们穿过粘液和其他生物屏障的扩散。我们分析了这个概念多年来是如何演变的，以及迄今为止在市场上销售的纳米药物方面获得的好处，并为读者提供了该主题的前景观点。
